undamentalytics Newsletter
Sign in

Traws Pharma, Inc. income statement

In fiscal 2025, Traws Pharma, Inc. reported revenue of $2.8m, up 1134.5% on the year before, operating income of −$17.9m (a -640.7% margin) and net income of $9.2m, or $0.82 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue14651116112000003
Research and development23535049262019171617711111312
General and administrative61617151097888989129
Operating income−28−22−62−64−24−24−26−23−22−25−16−20−20−142−18
Interest expense0900———————————
Income before tax−26−30−62−64−24−20−24−21−21−25−16−19−19−1679
Income tax——00000−000—————
Net income−26−30−63−64−24−20−24−21−22−25−16−19−19−1679
Diluted EPS−$2658.75−$2878.13−$1.53−$5512.50−$1976.25−$1665.00−$1003.75−$124.75−$37.25−$54.25−$0.96−$0.91−$22.57−$35.21$0.82
Diluted shares (average)——————24m——————2m8m
EBITDA−27−22−62−63−24−24−26−23−22−25−16−20−20−142−18

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EYPT vs TRAWTRAW vs TXMDCPHI vs TRAW

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Traws Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Traws Pharma, Inc.